Mercator MedSystems, Inc., an Emeryville, CA-based designer of small-scale mixture catheter system, got $11m in Series D value financing. The round was driven by Shenzhen Salubris Pharmaceuticals Co., with cooperation from current investors and other undisclosed new speculators.
"We are excited to announce that such a prominent Chinese pharmaceutical company is partnering with Mercator for the Bullfrog® Micro-Infusion Device's entry into the fastest growing medical market in the world," said Trent Reutiman, chief executive officer of Mercator. "Salubris has recently been investing in a robust and cutting-edge cardiovascular medical device portfolio in China. Their lead in the current round of financing is a strong vote of confidence in the potential of the Bullfrog Device to treat patients with peripheral arterial disease (PAD) and critical limb ischemia."
“We are committed to the development of interventional cardiovascular procedures utilizing the Bullfrog device and its long-term potential to deliver a combination of therapeutics within and across molecule classes and for a variety of diseases. The immediate opportunity of delivering an agent in below-the-knee vascular disease represents an exciting and large market in the PRC,” Salubris’ CEO Kevin Ye added.